Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
輝瑞/BioNTech更新的基於奧密克戎的新冠肺炎疫苗顯示對變體的更好反應
- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
- The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.
- Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months.
- A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.
- The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.
- Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower.
- The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.
- Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.
- Image by x3 from Pixabay
- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
- The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.
- Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months.
- A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.
- The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.
- Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower.
- The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.
- Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.
- Image by x3 from Pixabay
- 輝瑞(紐約證券交易所股票代碼：PFE)和BioNTech SE納斯達克(Sequoia Capital：BNTX)表示，針對奧密克戎冠狀病毒變異株的改良疫苗產生了更高的免疫應答。
- 兩家公司表示，僅針對BA.1奧密克戎亞型的30微克和60微克劑量的疫苗，針對該亞型的中和幾何滴度分別增加13.5倍和19.6倍。
- 另請閲讀： 輝瑞-生物技術新冠肺炎疫苗獲得FDA緊急使用許可，適用於年僅6個月的兒童.
- 同時包含重新設計的疫苗和原始疫苗的疫苗版本獲得了9.1倍和10.9倍的增長。
- 這一結果來自對1234名年齡在56歲或以上的人的試驗。兩家公司表示，參與者對注射的耐受性很好。
- 早期的實驗室研究表明，這兩種奧密克戎修飾的候選疫苗都能中和奧密克戎BA.4和BA.5亞型，儘管程度比BA.1小，效價大約低3倍。
- 未來幾周，兩家公司將繼續收集有關奧密克戎BA.4/BA.5的更多研究數據。
- 價格行動：週一收盤前，PFE股價下跌0.02%，至51.6美元，BNTX股價上漲3.07%，至138.15美元。
- 圖片來自Pixabay的X3
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！